Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR1900024325Phase 2Recruiting
Phase 2, open-label trial of dasatinib in acute myeloid leukemia (AML) (2 arms), sponsored by Children's Hospital of Soochow University. Primary endpoints: Tolerance of dasatinib 80 mg/m2 and Other adverse effects related to dasatinib. Started Jul 2019; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR1900024325.